Shanghai MicroPort MedBot Group Co. Ltd. has reported its unaudited consolidated interim results for the six months ended 30 June 2025. The Group recorded a revenue of RMB175.7 million, marking a significant increase of 77% compared to RMB99.2 million in the previous year. This growth was driven by the sales of medical devices and accessories, which accounted for RMB172.7 million of the revenue, recognized at a point in time, and service income of RMB3.0 million recognized over time. A noteworthy achievement during this period was the Group's milestone breakthrough in the commercialization of overseas markets, which resulted in overseas sales revenue of RMB102.4 million, a substantial increase of 189% year-on-year. The Group's strategy focused on enhancing cost and cash flow control, optimizing production processes, and improving operational management, contributing to these positive results. The Group also reported that the comprehensive order volume for its core products in laparoscopic, orthopedic, and vascular intervention accumulated nearly 150 units, with over 100 units installed globally. This development is reshaping the global surgical robot market landscape and competitive dynamics. The company continues to prioritize both domestic and overseas markets through a dual-track strategy, promoting complementary advantages and collaborative cooperation.